Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry. JAMA Neurol. 168. Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, Broderick J, ChatterjeeA, Jauch EC, Levine SR, et al; PRISMS Investigators. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. JAMA. 2018;320:156 169. Adams RJ, Cox M, Ozark SD, Kanter J, Schulte PJ, XianY, Fonarow GC, Smith EE, Schwamm LH. Coexistent sickle cell disease has no impact on the safety or outcome of lytic therapy in acute ischemic stroke: findings from Get With The Guidelines Stroke. Stroke. 2017;48:686 691. doi: 170. Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Janjua N, Divani AA. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology. 2006;66:1171 1174. doi: 171. IST Collaborative Group.Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute isch- aemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. Lancet Neurol. 2015;14:485 172. Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, PeetersA, FarrallAJ,AdamiA, Potter G, et al; IST-3 Collaborative Group. Effect of alteplase on the CT hyperdense artery sign and out- come after ischemic stroke. Neurology. 2016;86:118 125. doi: 173. Adeoye O, Sucharew H, Khoury J, Tomsick T, Khatri P, Palesch Y, Schmit PA, Pancioli AM, Broderick JP; for the CLEAR-ER, IMS III, and ALIAS Part 2 Investigators. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue- type plasminogen activator alone in acute ischemic stroke: propen- sity score-matched post hoc analysis. Stroke. 2015;46:461 464. doi: 174. 